Orphan Drug Development: Could We Be Seeing The End Of P Values?

 
• By Michael Cipriano
  
Letter P
P values for orphan products might never come into focus if FDA moves away from reliance on randomized clinical trials.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D